Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by toinv261on Feb 21, 2015 4:26pm
108 Views
Post# 23451594

RE:Combined ASSURE/SUSTAIN

RE:Combined ASSURE/SUSTAIN The following data is the data I was referring to in my posting of Feb 20th at 3:50. The prediction formulas for the following data are in the original posting.

I tried to insert a graph of the actual data and MACE predictions but I could not figure out how to do this on Stockhouse. The graph is quite striking. If anyone knows how to paste in a graph please let me know and I'll put it in.

      MACE Events From Combined SUSTAIN & ASSURE    
        Predicted Predicted
Time Test Data Predicted Control Control Control
in  Crestor + Crestor + Data cubed LN +
Days rvx-208 208 LN Crestor polynomial  time squared
0 0.0 -0.4 0.0 -0.5 -0.9
15 0.1 0.5 1.5 2.2 4.0
30 0.1 0.9 4.5 4.0 4.9
45 1.0 1.3 4.5 5.1 5.0
60 2.0 1.6 6.2 5.7 5.2
75 2.5 2.0 6.2 6.0 5.5
90 2.5 2.3 6.3 6.1 6.0
105 3.1 2.5 6.3 6.1 6.8
129 3.1 3.0 6.4 6.6 8.9
135 3.1 3.1 6.5 6.9 9.6
150 3.2 3.4 7.5 8.0 11.5
165 3.3 3.6 11.5 9.7 13.9
180 3.4 3.9 11.5 12.2 16.6
195 3.4 4.2 15.2 15.7 19.8
210 5.1 4.4 20.8 20.4 23.4
225   4.7   26.4 27.4
240   4.9   33.9 31.9
255   5.2   43.1 36.7
270   5.4   54.2 42.0
285   5.7     47.8
300   5.9      
315   6.2      
330   6.4      
345   6.6      
360   6.9      


If you put this data into a graphing program I think you'll get an idea of why Don seems to be smiling these days.

As I mentioned in the original post I was reminded of today on a science show called Quirks and Quarks was a quote from Yogi Berra and it was "Prediction is hard ...especially if it's about the future".

Keep in mind the all patients had diabetes mellitus and CVD and the control group was treated with Crestor and the test group was treated with Crestor plus rvx-208.

You can see clearly that at day 150 that MACE started to increase exponentially in the control group and within those treated with rvx-208 + Crestor the MACE rate was low and remained low through the 210 test period.

We all know that science must be replicated so hopefully we'll got moving on BETonMACE.

Cheers
Toinv   :)


Bullboard Posts